What is new in the treatment of Systemic Lupus Erythematosus?

Czech version

Authors: Martina Skácelová
Authors‘ workplace: III. interní klinika – nefrologická, revmatologická a endokrinologická, FN a LF UP Olomouc
Published in: Vnitř Lék 2022; 68(5): 273-278
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.059

Overview

Systemic lupus erythematosus treatment is targeted to achieve remission or low disease activity and protection from disease flares. A number of immunosupresive drugs in combination with glucocorticoids are used for this purpose and there is an increased possibility of the use of biologic treatment, especially of belimumab. Calcineurin inhibitor voclosporin is a novelty in lupus nephritis treatment. Another novelty is anifrolumab, a biologic drug which inhibits the activity of type I interferons. An integral part of care is the prevention of late disease complications, especially cardiovascular risk management.

Keywords:

Systemic lupus erythematosus – Lupus nephritis – voclosporin – belimumab – anifrolumab

Sources

1. Horák P, Skácelová M, Schubertová M. Život ohrožující projevy systémového lupusu a antifosfolipidového syndromu ve vnitřním lékařství. Vnitř Lék 2018;64(2):136-145.

2. Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/ American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6. PMID: 31385462; PMCID: PMC6827566.

3. Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019;78:736-745.

4. Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases. 2020;79:713-723.

5. Horák P, Tegzová D, Závada J et al. Doporučení ČRS pro léčbu nemocných se SLE. Čes Revmatol. 2013;21:110-122.

6. Ruiz‑Irastorza G, Ramos‑Casals M, Brito‑Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–8.doi:10.1136/ard.2008.101766.

7. Yap DYH, Chan TM. What is the ideal duration of maintenance therapy for lupus nephritis? Expert Rev Clin Immunol. 2022 Mar 19. doi: 10.1080/1744666X.2022.2056020. Epub ahead of print. PMID: 35306959.

8. Sciascia S, Radin M, Yazdany J et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev 2017;16:287–93. doi:10.1016/j.autrev.2017. 01. 010 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28147262.

9. Furie R, Rovin BH, Houssiau F et al.Two‑year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117-1128

10. Kraaij T, Kamerling SWA, de Rooij ENM et al. The NET‑effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 2018;91:45- 54.doi:10.1016/j.jaut.2018. 03. 003.

11. van Gelder T, Huizinga RB, Lisk L, Solomons N. Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrol Dial Transplant. 2022 Apr 25;37(5):917-922. doi: 10.1093/ndt/gfab022.

12. Rovin BH, Solomons N, Pendergraft WF 3rd et al. A randomized, controlled double- ‑blind study comparing the efficacy and safety of dose‑ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219-231.

13. Rovin BH, Teng YKO, Ginzler EM, Arriens C et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double‑blind, randomised, multicentre, placebo‑ controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/ S0140-6736(21)00578-X. Epub 2021 May 7. Erratum in: Lancet. 2021 May 29;397(10289):2048. PMID: 33971155.

14. Navarra SV, Guzmán RM, Gallacher AE et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‑ controlled, phase 3 trial. Lancet. 2011;377:721-731.

15. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo‑ controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. BLISS-76 Study Group. Arthritis Rheum. 2011;63:3918-3930.

16. Wallace DJ, Ginzler EM, Merrill JT et al. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5. PMID: 30771238; PMCID: PMC6617785.

17. Iaccarino L, Andreoli L, Bocci EB et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8.doi:10.1016/j. jaut.2017. 09. 004

18. van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343-9.doi:10.1136/annrheumdis-2011-200937

19. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately‑to‑severely active systemic lupus erythematosus: the randomized, double‑blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. PMID: 20039413; PMCID: PMC4548300.

20. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. PMID: 22231479.

21. Gomez Mendez LM, Cascino MD, Garg J et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13:1502-9.

22. Merrill JT, Furie R, Werth VP et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018 Nov 26;5(1): e000284. doi: 10.1136/lupus- 2018-000284. PMID: 30588322; PMCID: PMC6280909.

23. Furie RA, Morand EF, Bruce IN et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):E208.

24. Morand EF, Furie R, Tanaka Y et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211. Epub 2019 Dec 18.

25. Tummala R, Abreu G, Pineda L et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021 Feb;8(1):e000464. doi: 10.1136/lupus-2020-000464. PMID: 33597205; PMCID: PMC7893670.

26. Drosos GC, Vedder D, Houben E et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum, DiS. 2022 Jun;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2. PMID: 35110331.

27. Furer V, Rondaan C, Heijstek MW et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum, DiS. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14. PMID: 31413005.